Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 3/20 | 0.31 |
| ▸ | MMP8 | P22894 | 3/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21153239 | 1.00 | XIAP (0.38) | XIAPBIRC2MMP1MMEACE | |
| SCHEMBL14076482 | 1.00 | XIAP (0.38) | XIAPBIRC2MMP1MMEACE | |
| SCHEMBL6850696 | 0.89 | — | — | |
| SCHEMBL8260827 | 0.89 | — | — | |
| SCHEMBL8260376 | 0.89 | — | — | |
| SCHEMBL26740055 | 0.86 | XIAP (0.32) | XIAPBIRC2 | |
| SCHEMBL13337074 | 0.85 | GAA (0.33) | MMP1MMEACECPA1ACE2 | |
| SCHEMBL19934873 | 0.83 | ACE (0.43) | XIAPBIRC2MMP1MMEACE | |
| SCHEMBL23142756 | 0.83 | MME (0.47) | MMEACECPA1ACE2 | |
| SCHEMBL22475286 | 0.83 | MME (0.47) | MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922829-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | EPOR, LIFR, LNPEP | XIAP 1223/4885BIRC2 4469/4885MMP1 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.